Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated:  11/10/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated: 11/10/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated:  11/10/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated: 11/10/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated:  11/10/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated: 11/10/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated:  11/10/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated: 11/10/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated:  11/10/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
El Pueblo De Nuestra Señora De Los Ángeles De Porciúncula, CA
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Status: Enrolling
Updated: 11/10/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
El Pueblo De Nuestra Señora De Los Ángeles De Porciúncula, CA
Click here to add this to my saved trials
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated:  11/10/2017
Marin Cancer Care, Inc.
mi
from
Greenbrae, CA
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated: 11/10/2017
Marin Cancer Care, Inc.
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated:  11/10/2017
Scripps Cancer Center
mi
from
La Jolla, CA
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated: 11/10/2017
Scripps Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated:  11/10/2017
Collaborative Research Group
mi
from
Boca Raton, FL
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated: 11/10/2017
Collaborative Research Group
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated:  11/10/2017
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated: 11/10/2017
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated:  11/10/2017
University of Washington Medical Center
mi
from
Seattle, WA
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated: 11/10/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated:  11/10/2017
Greenslopes Private Hospital
mi
from
Greenslopes,
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study
Status: Enrolling
Updated: 11/10/2017
Greenslopes Private Hospital
mi
from
Greenslopes,
Click here to add this to my saved trials
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Tampa, FL
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Lebanon, NH
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Bronx, NY
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Philadelphia, PA
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Nashville, TN
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
San Antonio, TX
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Morgantown, WV
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Amsterdam,
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Amsterdam,
Click here to add this to my saved trials
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Duarte, CA
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Duarte, CA
Click here to add this to my saved trials
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Santa Monica, CA
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Detroit, MI
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Lebanon, NH
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
New Brunswick, NJ
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Greenville, SC
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Nashville, TN
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Tacoma, WA
VEG111485: A QTc Study of Pazopanib
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Characterization of Focal Liver Lesions With SONOVUE®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard
Status: Enrolling
Updated:  11/13/2017
Bracco Diagnostics Inc.
mi
from
Princeton, NJ
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Characterization of Focal Liver Lesions With SONOVUE®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard
Status: Enrolling
Updated: 11/13/2017
Bracco Diagnostics Inc.
mi
from
Princeton, NJ
Click here to add this to my saved trials
Phase I/II Calcitriol in Lung Cancer
A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/13/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Phase I/II Calcitriol in Lung Cancer
A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/13/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase I/II Calcitriol in Lung Cancer
A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/13/2017
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Phase I/II Calcitriol in Lung Cancer
A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/13/2017
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase I/II Calcitriol in Lung Cancer
A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/13/2017
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Phase I/II Calcitriol in Lung Cancer
A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/13/2017
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase I/II Calcitriol in Lung Cancer
A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/13/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Phase I/II Calcitriol in Lung Cancer
A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/13/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Billings Clinic
mi
from
Billings, MT
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Mayo Clinic Cancer Clinical Studies Unit
mi
from
Rochester, MN
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Mayo Clinic Cancer Clinical Studies Unit
mi
from
Rochester, MN
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
NYU Cancer Institute - Bellevue Hospital
mi
from
New York, NY
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
NYU Cancer Institute - Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Sarah Cannon Research Institute Drug Development Unit
mi
from
Nashville, TN
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Sarah Cannon Research Institute Drug Development Unit
mi
from
Nashville, TN
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Institut Claudius Regaud
mi
from
Toulouse Cedex,
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Institut Claudius Regaud
mi
from
Toulouse Cedex,
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
UCLA Neuro-Oncology Program
mi
from
Los Angeles, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
UCLA Neuro-Oncology Program
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors
Status: Enrolling
Updated:  11/13/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors
Status: Enrolling
Updated: 11/13/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
San Francisco, CA
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Hong Kong,
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Hong Kong,
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Mount Diablo Medical Center
mi
from
Concord, CA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Mount Diablo Medical Center
mi
from
Concord, CA
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Click here to add this to my saved trials